Journal article

Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category

Ian D Davis, Wanling Xie, Carmel Pezaro, Frede Donskov, J Connor Wells, Neeraj Agarwal, Sandy Srinivas, Takeshi Yuasa, Benoit Beuselinck, Lori A Wood, D Scott Ernst, Ravindran Kanesvaran, Jennifer J Knox, Allan Pantuck, Sadia Saleem, Ajjai Alva, Brian I Rini, Jae-Lyun Lee, Toni K Choueiri, Daniel YC Heng

European Urology | ELSEVIER | Published : 2017

University of Melbourne Researchers

Grants

Awarded by Australian National Health and Medical Research Council Practitioner Fellowship


Funding Acknowledgements

Ian D. Davis certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Ian D. Davis is supported by an Australian National Health and Medical Research Council Practitioner Fellowship (APP1102604) and research funding from Astellas and Exelixis. Carmel Pezaro has received honoraria from Janssen, Pfizer, Sanofi, Novartis, and Astellas; consulting fees from (Novartis; and travel and accommodation funding from Pfizer and Sanofi. Frede Donskov has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Neeraj Agarwal has received consulting fees from Pfizer, Exelixis, Cerulean, Argos, and Medivation. Takeshi Yuasa has received honoraria from Astellas, Novartis, and Pfizer. D. Scott Ernst has received honoraria from Bristol Myers Squibb, Roche, and Merck; consulting fees from Bristol Myers Squibb, Roche, Merck, and Novartis; and speaker bureau fees from Bristol Myers Squibb and Novartis. Lori A. Wood has received research funding from Pfizer, Exelixis, Bristol Myers Squibb, and Novartis, and travel and accommodation expenses from Novartis. Ravindran Kanesvaran has received honoraria from Pfizer, Novartis, Bayer, Astellas, Janssen, Mundipharma, and Sanofi; research funding from Sanofi; and travel and accommodation expenses from Pfizer and Astellas. Jennifer J. Knox has received research funding from Pfizer and Astra Zeneca), and consulting fees from Merck, Novartis, and Cellgene. Ajjai Alva has received honoraria and consulting fees from Prometheus, and research funding from Bayer, Merck, and Acerta. Jae-Lyun Lee has received honoraria from Pfizer and Astellas; consulting fees from Astellas; and research funding from Pfizer, Bayer, Janssen, Novartis, and Exelixis. Toni K. Choueiri has received research funding from Pfizer, Novartis, Merck, Exelixis, Tracon, GlaxoSmithKline, Bristol Myers Squibb, Peloton, and Roche. Wanling Xie, J. Connor Wells, Sandy Srinivas, Benoit Beuselinck, Allan Pantuck, Sadia Saleem, Brian I. Rini, and Daniel Y.C. Heng have nothing to disclose.